Sai Parenterals Q4 and FY26: a bigger platform, with CDMO at the center

Sai Parenterals Limited closed FY26 with a business that looks larger, more international, and more CDMO-led than it did a year ago. The headline number in Q4FY26 was consolidated revenue of ₹198 crore with EBITDA of ₹29 crore. This quarter also marked the first full-quarter consolidation of Noumed Pharmaceuticals Pty Limited in Australia, which management positioned as a step-change in regulated-market access and long-term contract visibility.

For the full year, consolidated revenue reached ₹381 crore with FY26 EBITDA of ₹47 crore and PAT of ₹14 crore. On a standalone basis, the picture was cleaner and more margin-consistent: FY26 revenue from operations rose to ₹162 crore, EBITDA increased to ₹33 crore, and PAT improved to ₹17 crore. The company also highlighted a sharp surge in CDMO revenue, up over 250 percent year on year, supported by deeper engagement with customers and the signing of long-term CDMO contracts.

The quarter, then, is less about a single-period beat and more about a transition. Sai Parenterals is moving from being a domestic branded generics and exports formulations player into a broader platform where dossiers, regulated accreditations, and multi-geo manufacturing plans are meant to compound over the next few years.

What the numbers say, and what they do not

The split between standalone and consolidated results matters because FY26 includes a partial year consolidation of Noumed (acquired on November 12, 2025). Consolidated FY26 margins look compressed versus Q4FY26 because the consolidated base includes an acquired business for part of the year and ongoing integration and growth investments. Q4FY26 EBITDA margin was 24 percent with PAT margin of 9 percent, while full-year consolidated EBITDA margin was 12 percent and PAT margin was 4 percent.

Standalone performance, in contrast, reflected the operating momentum of the Indian business. Standalone FY26 revenue rose 31 percent year on year to ₹162 crore. EBITDA grew 23 percent to ₹33 crore, though margin eased from 22 percent to 20 percent. PAT rose 64 percent to ₹17 crore, and PAT margin improved from 8 percent to 10 percent. The combination suggests that costs and mix shifted at the EBITDA line, but profitability improved at the bottom line.

Management tied the growth to CDMO momentum and customer engagement. In practical terms, that means a pipeline and contract-led approach rather than one-off spot manufacturing. It also increases the importance of dossiers and regulatory accreditations as durable competitive inputs.

Dossiers, registrations, and the logic of a regulated-market CDMO

Sai Parenterals describes itself as a diversified global pharmaceutical formulations company with capabilities in research, development, and manufacturing. The operating model has two anchors: branded generic formulations and CDMO products and services. The company points to a portfolio of 302 complex products across therapeutic areas and broad dosage forms, including liquid and dry powder injectables, tablets, capsules, liquid orals, sprays, ointments, and dry syrups.

What ties the story together is the emphasis on regulated and semi-regulated markets. The company highlighted 599 approved product registrations in regulated markets within its portfolio, including 456 approved in TGA Australia and 143 approvals in other countries. In FY26, Sai Parenterals expanded its portfolio by 93 dossiers, including 88 regulated and emerging market filings and 5 TGA Australia dossiers through Noumed. It also disclosed 67 dossiers under development, which management framed as visibility for export-led growth in FY27 and beyond.

Dossiers and registrations are not marketing assets. They are the route to market and a basis for customer negotiations in regulated markets. If Sai Parenterals can keep dossier development moving, and if the upgraded facilities obtain the targeted accreditations, the company can compete for more consistent business from multinational partners and pharmacy-chain supply programs.

This is where Noumed fits in. The acquisition of a 74.64 percent stake in Noumed Pharmaceuticals Pty Limited adds a commercial footprint in Australia and access to New Zealand through Noumed Pharmaceuticals Limited. The company emphasized that Noumed has exclusive long-term supply agreements with Australian pharmacy chains, which is meant to translate into higher revenue visibility. It also framed the opportunity with market sizing: the Australian CDMO market was valued at about 2 billion dollars in 2024 and expected to grow at about 11.2 percent CAGR, while the New Zealand CDMO market was valued at 0.56 billion dollars in 2025 and expected to grow at about 17.3 percent CAGR.

The strategic intent is clear. Sai Parenterals wants to be a preferred CDMO partner for regulated and semi-regulated markets, using dossiers, approvals, and a broader manufacturing footprint to win contracts that last.

Capacity, compliance, and the capital allocation test

For a formulations and injectables player, execution is often decided by a few hard variables: capacity, regulatory compliance, and the ability to scale without quality slips. Sai Parenterals spent a meaningful portion of its presentation on its facilities and the expansion plan.

In Hyderabad, the company operates three sterile injectable facilities (Units I, II, and IV). It also runs a TGA Australia approved manufacturing facility (Unit III), and a PIC or PIC/S approved cephalosporin facility (Unit IV) that is in the process of upgrading to EU GMP. The presentation also mentions capex infusion to add lyophilized and cartridge-based dosage forms.

The expansion plan shows a push to raise installed capacity and improve accreditations.

• Unit I injectables capacity is planned to rise from 42 million units pre-expansion to 78 million units post-expansion, with accreditations targeted to move from GMP to EU GMP, WHO GMP, and PIC or PIC/S. Expected completion is January 2027.
• Unit II injectables capacity is planned to rise from 15 million units to 21 million units, with accreditations moving from WHO GMP to EU GMP, WHO GMP, and PIC or PIC/S. Expected completion is January 2027.
• Unit III general oral dosage forms capacity is planned to rise from 240 million units to 451 million units, retaining TGA Australia, WHO GMP, and PIC or PIC/S accreditations. Capex is ₹111 crore with expected completion in October 2026.
• Unit IV cephalosporin oral dosage forms and injectables capacity is shown as 293 million units both pre and post, with accreditations planned to move from WHO GMP and PIC or PIC/S to EU GMP, WHO GMP, and PIC or PIC/S. Expected completion is January 2027.
• A dedicated R and D facility is planned with capex of ₹18 crore, expected completion in July 2027.
• Noumed is developing a manufacturing facility in Adelaide for tablets, liquid orals, and nasal sprays, with capex of AUD 53 million and completion targeted for Q4FY27. The presentation notes that an AUD 20 million grant has already been disbursed by the Australian Government.

The expansion timeline reveals how the next 18 to 24 months could be shaped. Unit III capacity is expected to come on stream earlier, by October 2026, while the EU GMP upgrade path for Units I, II, and IV is expected by January 2027. The Adelaide facility, targeted for Q4FY27, is positioned as the regulated-market manufacturing bridgehead.

Funding is also spelled out through the IPO proceeds. The company completed an IPO in March 2026 with a primary fund raise of ₹285 crore and listed on April 2, 2026. It allocated ₹111 crore to capacity expansion and upgradation of manufacturing facilities, ₹18 crore to a new R and D centre, ₹14 crore to repayment or prepayment of certain institutional borrowings, ₹33 crore to working capital, ₹36 crore to repayment of bridge and term loan related to the Noumed acquisition, ₹45 crore to general corporate purposes, and ₹28 crore to issue expenses.

This matters because it ties strategy to capital discipline. Upgradation and compliance are not optional if the goal is regulated markets. And working capital and debt repayments can influence how much flexibility the company retains while it scales.

A portfolio built through acquisitions, now asked to integrate

Sai Parenterals has used acquisitions to accelerate its manufacturing and regulatory footprint. The presentation calls out a track record of value-accretive acquisitions, including the acquisition of Unit III (a TGA Australia approved facility) in FY22 for ₹24 crore, Unit IV (a PIC or PIC/S approved facility) in FY23 for ₹11 crore, Revat Laboratories Private Limited in FY24 for ₹28 crore, and Noumed in FY25 for ₹129 crore. The company also noted that Units III and IV were acquired as assets and did not generate revenue prior to acquisition, while Revat was founded by current promoters and later became a wholly owned subsidiary.

The integration challenge now shifts from acquiring assets to extracting synergies across commercial, R and D, and infrastructure. The company laid out the intended logic.

Commercially, Sai Parenterals brings a proven manufacturing track record and a fast-growing exports and CDMO business. Noumed adds long-term supply agreements with pharmacy chains and a strong presence in Australia and New Zealand. The stated synergy is expansion of the global CDMO business into regulated and semi-regulated markets.

In R and D, Sai Parenterals points to its dedicated subsidiary SP Analytics, which is intended to enhance formulation research and quality capabilities, support new products, and accelerate regulatory dossiers. Noumed brings a large set of product registrations approved with TGA Australia at the time of acquisition. Together, management expects a dedicated R and D centre to drive launches across Australia, New Zealand, Southeast Asia, the Middle East, Latin America, and other markets.

Operationally, the combined manufacturing footprint spans Hyderabad and Ongole in India, and the under-construction Adelaide site in Australia. This multi-site network can be a strength if compliance and scheduling are tight. It can also be a risk if integration is slow or capex timelines slip.

Still, the contours of the plan are coherent. Sai Parenterals is investing in accreditations, capacity, dossiers, and an R and D centre, while using Noumed as a regulated-market channel and contract base.

What to watch from here

The FY26 presentation frames the year as the start of a new phase. The company ended the year with higher scale, a broadened geographic footprint, and a sharper focus on CDMO. But the proof will come from execution on a few measurable fronts.

First is the conversion of the 67 dossiers under development into approvals and commercial wins. Second is the delivery of planned facility upgrades and accreditation milestones, especially EU GMP progress at Units I, II, and IV. Third is how effectively Noumed’s long-term supply agreements translate into stable cash flows while the Adelaide facility is completed by Q4FY27.

Finally, investors should keep an eye on the relationship between growth and margins. Standalone EBITDA margin slipped from 22 percent to 20 percent even as PAT margin improved to 10 percent. Consolidated margins vary by period due to acquisition timing. As the business scales, the market will likely look for a steady-state margin profile that reflects the intended shift to higher-quality regulated-market work.

Sai Parenterals ended FY26 with a simple message: the platform is larger, the CDMO engine is stronger, and the company is allocating capital toward compliance, dossiers, and capacity that can support regulated-market growth. If execution stays on schedule, FY27 and FY28 are positioned as years where the benefits of this build-out become easier to see in reported numbers.